{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:28Z","timestamp":1772164768297,"version":"3.50.1"},"reference-count":63,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) T cells can effectively treat leukemias, but sustained antitumor responses can be hindered by a lack of CAR T-cell persistence. Cytotoxic effector T cells are short-lived, and establishment of CAR-T cells with memory to ensure immune surveillance is important. Memory T cells depend on cytokine support, with IL7 activation of the IL7 receptor (IL7R) being critical. However, IL7R surface expression is negatively regulated by exposure to IL7. We aimed to support CAR T-cell persistence by equipping CAR-T cells with a sustained IL7R\u03b1 signal. We engineered T cells to constitutively secrete IL7 or to express an anti\u2013acute myeloid leukemia\u2013targeted IL7R\u03b1\u2013chimeric cytokine receptor (CCR) and characterized the phenotype of these cell types. Canonical downstream signaling was activated in CCR-T cells with IL7R activation. When coexpressed with a cytotoxic CAR, functionality of both the CCR and CAR was maintained. We designed hybrid CAR\u2013CCR and noted membrane proximity of the intracellular domains as vital for signaling. These data show cell-intrinsic cytokine support with canonical signaling, and functionality can be provided via expression of an IL7R\u03b1 domain whether independently expressed or incorporated into a cytotoxic CAR for use in anticancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>To improve the phenotype of tumor-directed T-cell therapy, we show that provision of cell-intrinsic IL7R-mediated signaling is preferable to activation of cells with exogenous IL7. We engineer this signaling via independent receptor engineering and incorporation into a CAR and validate maintained antigen-specific cytotoxic activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0286","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:12:08Z","timestamp":1724667128000},"page":"2359-2373","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6100-1985","authenticated-orcid":false,"given":"Stamatia C.","family":"Vorri","sequence":"first","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-0839","authenticated-orcid":false,"given":"Natalie J.","family":"Holl","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-0701","authenticated-orcid":false,"given":"Michael","family":"Leeming","sequence":"additional","affiliation":[{"name":"Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Victoria, Australia. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3856-5109","authenticated-orcid":false,"given":"Petya","family":"Apostolova","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3"},{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland. 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6724-8399","authenticated-orcid":false,"given":"Andrew","family":"Marple","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-0576","authenticated-orcid":false,"given":"Jonas W.","family":"Ravich","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-7518","authenticated-orcid":false,"given":"Ata","family":"Canbaz","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-3546","authenticated-orcid":false,"given":"Ruyan","family":"Rahnama","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-5969","authenticated-orcid":false,"given":"Jun","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"},{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1004-067X","authenticated-orcid":false,"given":"Arjun","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3887-4443","authenticated-orcid":false,"given":"Adam D.","family":"Fearnow","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9288-8443","authenticated-orcid":false,"given":"Scott T.R.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Chemical Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, Maryland. 7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-5439","authenticated-orcid":false,"given":"Erika L.","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-1034","authenticated-orcid":false,"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-1683","authenticated-orcid":false,"given":"Challice L.","family":"Bonifant","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"2025040317230775100_bib1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025040317230775100_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"2025040317230775100_bib3","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2025040317230775100_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2025040317230775100_bib5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2025040317230775100_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2025040317230775100_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2025040317230775100_bib8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"2025040317230775100_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding subset diversity in T cell memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"2025040317230775100_bib10","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"2025040317230775100_bib11","doi-asserted-by":"crossref","first-page":"1242454","DOI":"10.1126\/science.1242454","article-title":"Fueling immunity: insights into metabolism and lymphocyte function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"key":"2025040317230775100_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"2025040317230775100_bib13","doi-asserted-by":"crossref","first-page":"273ra13","DOI":"10.1126\/scitranslmed.3010314","article-title":"In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells","volume":"7","author":"Biasco","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025040317230775100_bib14","doi-asserted-by":"crossref","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"2025040317230775100_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of na\u00efve and memory CD8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat Immunol"},{"key":"2025040317230775100_bib16","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.20030725","article-title":"IL-7 promotes the transition of CD4 effectors to persistent memory cells","volume":"198","author":"Li","year":"2003","journal-title":"J Exp Med"},{"key":"2025040317230775100_bib17","doi-asserted-by":"crossref","first-page":"747324","DOI":"10.3389\/fimmu.2021.747324","article-title":"Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"2025040317230775100_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.it.2005.01.004","article-title":"IL-7: maintaining T-cell memory and achieving homeostasis","volume":"26","author":"Bradley","year":"2005","journal-title":"Trends Immunol"},{"key":"2025040317230775100_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by gamma(c) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2025040317230775100_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nri2023","article-title":"Interleukin-7 receptor expression: intelligent design","volume":"7","author":"Mazzucchelli","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2025040317230775100_bib21","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1084\/jem.20020067","article-title":"Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells","volume":"195","author":"Kieper","year":"2002","journal-title":"J Exp Med"},{"key":"2025040317230775100_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1172\/JCI200523134","article-title":"Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool","volume":"115","author":"Melchionda","year":"2005","journal-title":"J Clin Invest"},{"key":"2025040317230775100_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri1052","article-title":"Cytokine control of memory T-cell development and survival","volume":"3","author":"Schluns","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2025040317230775100_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1078-0432.CCR-09-1303","article-title":"Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy","volume":"16","author":"Sport\u00e8s","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025040317230775100_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13613-023-01109-w","article-title":"Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial","volume":"13","author":"Daix","year":"2023","journal-title":"Ann Intensive Care"},{"key":"2025040317230775100_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.cji.0000210386.55951.c2","article-title":"IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells","volume":"29","author":"Rosenberg","year":"2006","journal-title":"J Immunother"},{"key":"2025040317230775100_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/eji.200939271","article-title":"Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant","volume":"40","author":"Nam","year":"2010","journal-title":"Eur J Immunol"},{"key":"2025040317230775100_bib28","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"2025040317230775100_bib29","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cts.12800","article-title":"hIL-7-hyFc, A long-acting IL-7, increased absolute lymphocyte count in healthy subjects","volume":"13","author":"Lee","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2025040317230775100_bib30","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","article-title":"CD28-\u03b6 CAR T cells resist TGF-\u03b2 repression through IL-2 signaling, which can Be mimicked by an engineered IL-7 autocrine loop","volume":"26","author":"Golumba-Nagy","year":"2018","journal-title":"Mol Ther"},{"key":"2025040317230775100_bib31","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves nkg2d-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025040317230775100_bib32","doi-asserted-by":"crossref","first-page":"734593","DOI":"10.3389\/fonc.2021.734593","article-title":"IL-7 and CCR2b Co-Expression-Mediated enhanced CAR-T survival and infiltration in solid tumors","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"2025040317230775100_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025040317230775100_bib34","doi-asserted-by":"crossref","first-page":"12506","DOI":"10.1038\/s41598-022-16616-2","article-title":"Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"2025040317230775100_bib35","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.4049\/jimmunol.176.11.6702","article-title":"IL-7R alpha gene expression is inversely correlated with cell cycle progression in IL-7-stimulated T lymphocytes","volume":"176","author":"Swainson","year":"2006","journal-title":"J Immunol"},{"key":"2025040317230775100_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1158\/2326-6066.CIR-18-0748","article-title":"T-Cell activity against AML improved by dual-targeted T cells stimulated through T-cell and IL7 receptors","volume":"7","author":"Krawczyk","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2025040317230775100_bib37","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov"},{"key":"2025040317230775100_bib38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/CJI.0b013e318053ed8e","article-title":"New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells","volume":"30","author":"Du","year":"2007","journal-title":"J Immunother"},{"key":"2025040317230775100_bib39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"2025040317230775100_bib40","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jcyt.2018.07.005","article-title":"Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells","volume":"20","author":"Zolov","year":"2018","journal-title":"Cytotherapy"},{"key":"2025040317230775100_bib41","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","article-title":"T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells","volume":"108","author":"Vera","year":"2006","journal-title":"Blood"},{"key":"2025040317230775100_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41596-018-0097-3","article-title":"Systemic AAV vectors for widespread and targeted gene delivery in rodents","volume":"14","author":"Challis","year":"2019","journal-title":"Nat Protoc"},{"key":"2025040317230775100_bib43","doi-asserted-by":"crossref","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025040317230775100_bib44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.omtm.2020.02.003","article-title":"Optimized assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients","volume":"17","author":"Kunz","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025040317230775100_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","article-title":"Single-pot, solid-phase-enhanced sample preparation for proteomics experiments","volume":"14","author":"Hughes","year":"2019","journal-title":"Nat Protoc"},{"key":"2025040317230775100_bib46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/pmic.201000722","article-title":"Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells","volume":"11","author":"Wang","year":"2011","journal-title":"Proteomics"},{"key":"2025040317230775100_bib47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/pr300624g","article-title":"Statistical inference from multiple iTRAQ experiments without using common reference standards","volume":"12","author":"Herbrich","year":"2013","journal-title":"J Proteome Res"},{"key":"2025040317230775100_bib48","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat Protoc"},{"key":"2025040317230775100_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat Methods"},{"key":"2025040317230775100_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.2517-6161.1982.tb01195.x","article-title":"The statistical analysis of compositional data","volume":"44","author":"Aitchison","year":"1982","journal-title":"J R Stat Soc"},{"key":"2025040317230775100_bib51","article-title":"compositions: compositional data analysis","author":"van den Boogaart","year":"2024"},{"key":"2025040317230775100_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nbt765","article-title":"A general method for the covalent labeling of fusion proteins with small molecules in vivo","volume":"21","author":"Keppler","year":"2003","journal-title":"Nat Biotechnol"},{"key":"2025040317230775100_bib53","doi-asserted-by":"crossref","first-page":"9955","DOI":"10.1073\/pnas.0401923101","article-title":"Labeling of fusion proteins with synthetic fluorophores in live cells","volume":"101","author":"Keppler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317230775100_bib54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/cb800025k","article-title":"HaloTag: a novel protein labeling technology for cell imaging and protein analysis","volume":"3","author":"Los","year":"2008","journal-title":"ACS Chem Biol"},{"key":"2025040317230775100_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025040317230775100_bib56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"2025040317230775100_bib57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12216","article-title":"CD3\u03b6-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy","volume":"175","author":"Bridgeman","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025040317230775100_bib58","doi-asserted-by":"crossref","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"2025040317230775100_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41423-018-0183-z","article-title":"Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling","volume":"17","author":"Wan","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025040317230775100_bib60","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317230775100_bib61","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3390\/cells12182261","article-title":"Nanoscale CAR organization at the immune synapse correlates with CAR-T effector functions","volume":"12","author":"Sajman","year":"2023","journal-title":"Cells"},{"key":"2025040317230775100_bib62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025040317230775100_bib63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Adv"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0286\/3489877\/crc-24-0286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2359\/3495239\/crc-24-0286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2359\/3495239\/crc-24-0286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:03:45Z","timestamp":1743728625000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/9\/2359\/748376\/Activation-of-Cell-Intrinsic-Signaling-in-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0286","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.26968847.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968862.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968844.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968835.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968829.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968862","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968844","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968856","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968838.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968832.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727918","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968826.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727936","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968859.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727921","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968841.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968841","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968853","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968847","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968856.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968859","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968829","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968850.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26968853.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727933","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7439354.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7439354","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}